221 related articles for article (PubMed ID: 21339488)
1. Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
Hohlfeld R; Barkhof F; Polman C
Neurology; 2011 Feb; 76(8 Suppl 3):S28-37. PubMed ID: 21339488
[TBL] [Abstract][Full Text] [Related]
2. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
3. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
4. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
5. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
6. Sphingosine 1-phosphate receptor modulator fingolimod (FTY720) does not promote remyelination in vivo.
Hu Y; Lee X; Ji B; Guckian K; Apicco D; Pepinsky RB; Miller RH; Mi S
Mol Cell Neurosci; 2011 Sep; 48(1):72-81. PubMed ID: 21740973
[TBL] [Abstract][Full Text] [Related]
7. Impact of sphingosine 1-phosphate modulation on immune outcomes.
Pinschewer DD; Brinkmann V; Merkler D
Neurology; 2011 Feb; 76(8 Suppl 3):S15-9. PubMed ID: 21339486
[TBL] [Abstract][Full Text] [Related]
8. [Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Tian YL; Jin J; Wang XJ
Yao Xue Xue Bao; 2012 Jan; 47(1):7-17. PubMed ID: 22493799
[TBL] [Abstract][Full Text] [Related]
9. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
Lee CW; Choi JW; Chun J
Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
[TBL] [Abstract][Full Text] [Related]
10. Fingolimod: a novel immunosuppressant for multiple sclerosis.
Brown BA; Kantesaria PP; McDevitt LM
Ann Pharmacother; 2007 Oct; 41(10):1660-8. PubMed ID: 17785617
[TBL] [Abstract][Full Text] [Related]
11. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.
Brinkmann V
Pharmacol Ther; 2007 Jul; 115(1):84-105. PubMed ID: 17561264
[TBL] [Abstract][Full Text] [Related]
12. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
13. Fingolimod for the treatment of relapsing multiple sclerosis.
Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
[TBL] [Abstract][Full Text] [Related]
14. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
Ingwersen J; Aktas O; Kuery P; Kieseier B; Boyko A; Hartung HP
Clin Immunol; 2012 Jan; 142(1):15-24. PubMed ID: 21669553
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
17. Emerging oral agents for multiple sclerosis.
Fox EJ
Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
[TBL] [Abstract][Full Text] [Related]
18. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
García-Merino JA; Sánchez AJ
Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
Chiba K; Kataoka H
Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):24-5. PubMed ID: 18421849
[No Abstract] [Full Text] [Related]
20. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications.
Camm J; Hla T; Bakshi R; Brinkmann V
Am Heart J; 2014 Nov; 168(5):632-44. PubMed ID: 25440790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
